Maflucoxib is a new generation of compounds with a unique mechanism of action that specifically inhibits cyclooxygenase-2 (COX-2). Inflammatory stimulation can induce COX-2 production, leading to the synthesis and accumulation of inflammatory prostaglandins, especially prostaglandin E2, causing inflammation, edema, and pain. Mofamotidine can inhibit COX-2 and prevent the production of inflammatory prostaglandins, achieving anti-inflammatory, analgesic, and antipyretic effects.